We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Vallon Pharmaceuticals, Inc. (“Vallon” or the “Company”) (NASDAQ: VLON), in connection with the proposed merger of the Company with GRI Bio, Inc. (“GRI Bio”).  Under the merger agreement, Vallon will acquire 100% of the outstanding equity interests of GRI Bio, by means of reverse triangular merger of a wholly owned subsidiary of Vallon with and into GRI Bio, with GRI Bio surviving as a wholly owned subsidiary of Vallon.  Upon completion of the transaction, Vallon shareholders are expected to only own approximately 17% of the combined company, while GRI Bio shareholders are expected to own approximately 83%.

Weiss Law is investigating whether (i) Vallon’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration adequately compensates Vallon’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.